The rate of osteoblast apoptosis is a critical determinant of the rate of bone formation. Because the calciumbinding protein calbindin-D 28k has anti-apoptotic properties in neuronal cells and lymphocytes, we searched for the presence of this protein in osteoblastic cells and investigated whether it can modify their response to proapoptotic signals. Calbindin-D 28K was expressed at low levels in several osteoblastic cell lines and at high levels in primary cultures of murine osteoblastic cells. Transient transfection of rat calbindin-D 28k cDNA blocked tumor necrosis factor ␣ (TNF␣)-induced apoptosis in osteoblastic MC3T3-E1 cells, as determined by cell viability and nuclear morphology of cells cotransfected with the green fluorescent protein targeted to the nucleus, whereas transfection of the empty vector had no effect. Calbindin-D 28k levels in several stably transfected MC3T3-E1 lines were directly related to protection from TNF␣-induced apoptosis. Purified rat calbindin-D 28k markedly reduced the activity of caspase-3, a critical molecule for the degradation phase of apoptosis, in a cell-free assay. In addition, cell extracts from MC3T3-E1 cells expressing high levels of calbindin-D 28k decreased caspase-3 activity, compared with extracts from vector-transfected cells. This effect was apparently unrelated to the calcium binding properties of calbindin, as chelation of calcium by EGTA or addition of other calcium-binding proteins such as calbindin-D 9k , S100, calmodulin, and osteocalcin, did not affect caspase-3 activity. Last, calbindin-D 28k interacts with the active form of caspase-3 as demonstrated by a GST pull-down assay. These results demonstrate that calbindin-D 28k is a biosynthetic product of osteoblasts with a role in the regulation of apoptosis. They also reveal that the antiapoptotic properties of calbindin-D 28k may result not only from calcium buffering but also from the ability of the protein to interact with and to inhibit caspase-3 activity, a property that is independent of its calcium binding capability.
The rate of osteoblast apoptosis is a critical determinant of the rate of bone formation. Because the calciumbinding protein calbindin-D 28k has anti-apoptotic properties in neuronal cells and lymphocytes, we searched for the presence of this protein in osteoblastic cells and investigated whether it can modify their response to proapoptotic signals. Calbindin-D 28K was expressed at low levels in several osteoblastic cell lines and at high levels in primary cultures of murine osteoblastic cells. Transient transfection of rat calbindin-D 28k cDNA blocked tumor necrosis factor ␣ (TNF␣)-induced apoptosis in osteoblastic MC3T3-E1 cells, as determined by cell viability and nuclear morphology of cells cotransfected with the green fluorescent protein targeted to the nucleus, whereas transfection of the empty vector had no effect. Calbindin-D 28k levels in several stably transfected MC3T3-E1 lines were directly related to protection from TNF␣-induced apoptosis. Purified rat calbindin-D 28k markedly reduced the activity of caspase-3, a critical molecule for the degradation phase of apoptosis, in a cell-free assay. In addition, cell extracts from MC3T3-E1 cells expressing high levels of calbindin-D 28k decreased caspase-3 activity, compared with extracts from vector-transfected cells. This effect was apparently unrelated to the calcium binding properties of calbindin, as chelation of calcium by EGTA or addition of other calcium-binding proteins such as calbindin-D 9k , S100, calmodulin, and osteocalcin, did not affect caspase-3 activity. Last, calbindin-D 28k interacts with the active form of caspase-3 as demonstrated by a GST pull-down assay. These results demonstrate that calbindin-D 28k is a biosynthetic product of osteoblasts with a role in the regulation of apoptosis. They also reveal that the antiapoptotic properties of calbindin-D 28k may result not only from calcium buffering but also from the ability of the protein to interact with and to inhibit caspase-3 activity, a property that is independent of its calcium binding capability.
Bone mass is largely determined by the number of bone forming (osteoblasts) and bone resorbing (osteoclasts) cells present in the basic multicellular units responsible for the regeneration of the adult skeleton (1) . Similarly to other regenerating tissues, the number of bone cells is controlled by changes not only in the production of mature cells but also in their survival (2, 3) . Recent evidence indicates that apoptosis represents the most common fate of osteoblasts during physiologic bone remodeling (4) and that agents that influence the rate of bone formation and bone mass control osteoblast apoptosis in vitro and in vivo (5) (6) (7) .
Signals that initiate apoptosis trigger the so-called private pathways of death, which are specific for particular groups of stimuli and lead to conversion of procaspases to active caspases. Activation of caspase-3 is the point of convergence of the private pathways, after which specific substrates are cleaved leading to the common executive phase of apoptosis. The end result of this cascade is chromatin condensation, nuclear fragmentation, increase in cell membrane permeability, and ultimately cell death (8, 9) .
Even though the participation of calcium in apoptosis is still controversial, several pieces of evidence indicate a role for calcium in the initiation as well as in the degradation phase of apoptosis (10, 11) . Consistent with this, agents that chelate intracellular calcium, including the calcium-binding protein calbindin-D 28k , have been shown to block apoptosis induced by different pro-apoptotic pathways (12) (13) (14) . Calbindin-D 28k is expressed in high levels in intestine and kidney, tissues in which it may function as a facilitator of calcium diffusion. Expression of calbindin-D 28k has been also reported in many other tissues, such as pancreas and brain (15) . In addition, the protein has been detected by in situ hybridization in developing and adult rat mineralized tissues (16, 17) . Interestingly, the susceptibility of neurons to apoptosis seems to be inversely related to the level of expression of calbindin in vivo (18, 19) . Furthermore, overexpression of calbindin prevents apoptosis in cultured neural cells expressing mutant presenilin-1, a gene whose aberrations account for approximately 50% of all cases of familial Alzheimer's disease (14) . Likewise, lymphocytes expressing higher levels of calbindin are more resistant to apoptosis induced by several stimuli (13) . The anti-apoptotic property of calbindin-D 28k has been attributed to its ability to chelate calcium. The results of the present study demonstrate that calbindin-D 28k is produced by osteoblastic cells and protects them from apoptosis. In addition, they reveal that the antiapoptotic properties of calbindin-D 28k in osteoblasts, as well as in other cell types, may result not only from calcium buffering, but also from the ability of the protein to inhibit caspase-3 activity, which is independent of the calcium binding capability of calbindin-D 28k .
EXPERIMENTAL PROCEDURES
Materials-Calbindin-D 28k was purified from rat kidney, as described previously (20) . Purified rat bone osteocalcin was purchased from Biomedical Technologies Inc. (Stoughton, MA). Purified bovine calbindin-D 9k , S100, calmodulin, murine gelsolin, and antibody to ␤-actin were purchased from Sigma. The caspase-3 activity assay kit, recombinant and purified human caspase-3, and the cell-permeable caspase-3 inhibitor Asp-Glu-Val-Asp-aldehyde (DEVD-CHO) 1 were obtained from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA). Recombinant murine tumor necrosis factor ␣ (TNF ␣) was purchased from R & D Systems (Minneapolis, MN) . SuperFect, Lipofectin, and ECL reagents were purchased from Qiagen (Santa Clarita, CA), Life Technologies, Inc., and NEN Life Science Products, respectively. The enhanced green fluorescent protein (CLONTECH Laboratories, Palo Alto, CA) containing the SV40 large T antigen nuclear localization sequence (21) (27) . Murine osteocytic MLO-Y4 cells (provided by Dr. Lynda Bonewald, University of Texas Health Center at San Antonio, TX) were cultured as described previously (28) . All culture media contained 100 units/ml penicillin and 100 g/ml streptomycin. Cultures were kept in a humidified atmosphere of 5% CO 2 in air at 37°C. as described previously (14) . After 4 weeks of selection with 400 g/ml hygromycin, colonies were handpicked under sterile conditions and propagated in 24-well plates.
Apoptosis-Apoptotic cells were quantified by trypan blue staining. We have previously demonstrated that the percentage of cells exhibiting trypan blue staining correlates with the percentage of terminal deoxynucleotidyl transferase-mediated nick end labeling-labeled cells, indicating that apoptotic osteoblasts could be reliably quantified by either method (4, 6, 7, 29) . In the experiment of Fig. 3 , cells were plated on chamber slides and transfected with the expression vectors pREP4 alone or pREP4-calbindin-D 28k together with the expression vector for nuclear green fluorescent protein. Forty-eight hours after transfection, cells were exposed to 1 nM TNF␣ for 16 h. Subsequently, cells were fixed, mounted, and examined with a Zeiss confocal laser scanning microscope. The percentage of apoptosis was determined by examining the nuclear morphology of Ͼ150 transfected (fluorescent) cells. Confocal fluorescent images were obtained using an argon laser of 488 nm wavelength and a 530-nm-long pass barrier filter.
Western Blot Analysis-Cell lysates, protein electrophoresis, and Western blot analysis were performed as described previously (27) . Membranes were incubated overnight at 4°C with an antibody to either calbindin-D 28k (30) or ␤-actin, followed by incubation for 1 h with the corresponding secondary antibody conjugated with horseradish peroxidase. Blots were developed by ECL. Quantification of the intensity of the bands in the autoradiograms was performed by laser densitometry.
Radioimmunoassay-Calbindin protein levels were determined by radioimmunoassay using antiserum against rat renal calbindin and purified rat renal calbindin-D 28k as standard, as described previously (30) .
Caspase-3 Activity-Caspase-3 was measured in a cell-free assay by determining the degradation of the colorimetric substrate DEVD-paranitroanilide (DEVD-pNA) that contains the amino acid sequence of the caspase-3 cleavage site in poly(ADP-ribose)polymerase (31) . Thirty units of human recombinant caspase-3 were combined with 200 M DEVD-pNA in the absence or presence of 0.1 M DEVD-CHO inhibitor, or 0.5 or 1 g of purified calbindin D 28k , or 1 g of the calcium binding proteins calmodulin, S100, calbindin-D 9K , or osteocalcin, or 1 mM EGTA, or lysates containing 30 g of proteins from clone c5 or vectortransfected cells. Enzyme activity was calculated based on absorption values at 405 nm.
In Vitro Digestion with Caspase-3-Purified gelsolin (3 g) or calbindin-D 28k (3 g) and caspase-3 (50 ng) were incubated at 37°C for 10 min in 6 mM Tris-HCl (pH 7.5), 1.2 mM CaCl 2 , 1.5 mM dithiothreitol, 1.5 mM MgCl 2 , and 1 mM KCl. Samples were analyzed by SDS-PAGE followed by staining with Coomassie Blue.
Preparation of GST Fusion Proteins and in Vitro Association
Assay-GST-calbindin-D 28k (provided by Dr. T.-L. Huo, University of Arizona, Tucson, AZ) or GST plasmids were used to transform Escherichia coli DH5␣ strain. Isolated colonies resulting from overnight cultures were grown in Luria broth containing 100 g/ml of ampicillin for 3 h and induced with 0.2 mM isopropyl-␤-D-galactoside for 2 h. Bacterial cultures were centrifuged and sonicated three times for 10 s in chilled phosphate-buffered saline containing 0.5 mM CaCl 2 . GST fusion proteins were immobilized on glutathione beads by incubation at 4°C for 2 h and washed three times with phosphate-buffered saline containing 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml apoprotenin, and 1 g/ml leupeptin. 500 ng of GST-CaBP 28k or GST were incubated with 200 or 600 ng of purified caspase-3 in 50 l of buffer containing 6.0 mM Tris (pH 7.4), 1.2 mM CaCl 2 , 1.5 mM dithiothreitol, 1.5 mM MgCl 2 , and 1.0 mM KCl for 1 h. Bound proteins were washed four times with phosphate-buffered saline containing 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 1 g/ml leupeptin, eluted in protein electrophoresis buffer, and resolved in 10% SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membrane and immunoblotted with rabbit caspase-3 antiserum (provided by Dr. J. C. Reed, the Burnham Institute, La Jolla, CA).
Statistical Analysis-Data were analyzed by one-way analysis of variance, and the Student-Keuls-Newman method was used to estimate the level of significance of differences between means. The effect of TNF treatment and calbindin-D 28k overexpression on the proportion of apoptotic cells in the experiment of Fig. 3 was analyzed using exact procedures for logistic regression (32) (LogXact software; CYTEL Software Corp.; Cambridge, MA). Following this, individual pair-wise comparisons of experimental groups were conducted using exact 2 tests, adjusting the p values with a Bonferroni correction. All p values (unadjusted for logistic regression; Bonferroni-adjusted for individual group comparisons) were compared with an ␣ value of 0.05 to determine significance.
RESULTS AND DISCUSSION
Calbindin-D 28k Is Expressed in Cells of the Osteoblastic Lineage-The expression of calbindin-D 28k in several cells of the osteoblastic lineage was investigated by Western blot analysis (Fig. 1) . Compared with kidney, a tissue known to produce calbindin, transformed murine MC3T3-E1, rat ROS17.2, and human MG-63 osteoblastic cell lines, the bone marrow-derived stromal/osteoblastic ϩ/ϩLDA11 and MBA13 cell lines, or the murine MLO-Y4 osteocytic cell line expressed little, if any, calbindin-D 28k , as could be detected by a rabbit anti-calbindin antibody that recognizes rodent and human calbindin (30) . On the other hand, nontransformed osteoblastic cells isolated from neonatal murine calvaria expressed much higher levels of the protein. 
Overexpression of Calbindin-D 28k Suppresses the Apoptotic
Response of Osteoblastic Cells-Recent evidence has suggested the involvement of apoptosis in the regulation of osteoblastic bone formation and osteoclastic bone resorption during adult bone remodeling (2, 3). To examine whether expression levels of calbindin-D 28k had an effect on apoptosis of osteoblastic cells, MC3T3-E1 cells were transiently transfected with two different expression vectors (pBSR␣ and pREP4) containing the calbindin-D 28k cDNA. As expected, transfectants expressed much higher levels of the protein compared with either parental cells or cells transfected with the empty vectors ( Fig. 2A) . Consistent with our previous observations demonstrating pro-apoptotic effects of TNF␣ in MC3T3-E1 cells (4), TNF induced apoptosis in cells transfected with either vector alone. In contrast, calbindin-D 28k transfectants were resistant to TNF-induced apoptosis (Fig. 2B) . In full agreement with these results, TNF␣ induced nuclear fragmentation of MC3T3-E1 cells transfected with empty pREP4 vector, as demonstrated by confocal microscopy of cells cotransfected with nuclear green fluorescent protein (10.8% versus 78.1% apoptotic cells in ϪTNF␣ and ϩTNF␣, respectively). However, the proapoptotic effect of TNF␣ was significantly attenuated in cells transfected with calbindin cDNA (0% versus 20.1% apoptotic cells in ϪTNF␣ and ϩTNF␣, respectively) (Fig. 3) . TNF significantly (p Ͻ 0.0001) increased, while calbindin significantly (p Ͻ 0.0001) decreased the proportion of apoptotic cells, as determined by exact logistic regression. Bonferroni-adjusted pair-wise comparisons of all experimental groups yielded significant differences in the proportion of apoptotic cells between all experimental conditions except the vector alone group versus the calbindin ϩTNF group (p Ͻ 0.31), indicating that overexpression of calbindin-D 28k counteracted the pro-apoptotic effect of TNF␣. In further support for a relationship between calbindin and protection of apoptosis, the relative expression of calbindin-D 28k in MC3T3-E1 cells stable transfectants (clones c1, c3, and c5) corresponded closely to the ability of these transfectants to resist TNF-induced apoptosis (Fig. 4) .
Calbindin-D 28k Directly Inhibits Caspase-3 Activity in a Cellfree Assay-From the caspases identified to date, caspase-3 (CPP32/Yama/Apopain) is the most intensively studied. Caspase-3 normally exists in the cytosolic fraction of most mammalian cells and has been suggested to be an important mediator of apoptosis in response to multiple signals, including cytokines (31, 33, 34) . To address the possibility that the antiapoptotic properties of calbindin were due to direct effects on caspase-3, the effect of calbindin on the activity of this protease was determined (Fig. 5 ). Caspase-3 activity was assayed by measuring the degradation of the colorimetric peptide DEVDpara-nitroanilide. As expected, the activity of caspase-3 was completely inhibited by the specific caspase-3 inhibitor peptide DEVD-CHO. Strikingly, rat purified calbindin also markedly reduced the activity of caspase-3 (Fig. 5A) . Furthermore, cell extracts from MC3T3-E1 cells expressing high levels of calbindin-D 28k (c5) decreased by 30% caspase-3 activity, whereas extracts from vector-transfected cells did not change it significantly (Fig. 5B) . Considering that the inhibition of caspase-3 activity by 0.5 g of purified calbindin was about 70% (Fig. 5A ), 30 ng of calbindin contained in 30 g of protein from c5 cells (Fig. 4) should induce an inhibition of about 5%. This difference could be due to loss of some activity of calbindin during the purification process that makes difficult comparing the effects of purified versus c5 cell-derived calbindin. The inhibitory effect of calbindin on caspase-3 activity was apparently unrelated to its calcium binding properties, as chelation of calcium in the reaction buffer by EGTA did not affect the activity of the enzyme. Moreover, the calcium-binding proteins calmodulin, S100, calbindin-D 9K , and osteocalcin did not affect caspase-3 activity (Fig. 5A) . Previous studies indicated that calbindin, by buffering calcium, suppresses apoptosis of susceptible cells in the nervous system when induced by agents that increase intracellular calcium, including excitatory amino acids and TNF␣ (14, (35) (36) (37) . Mechanisms involved in this suppression include reduction of oxidative stress and preservation of mitochondrial function (14) . It was suggested that calbindin could inhibit the release of cytochrome c from the mitochondria, which is needed for the activation of caspase-3, by preventing calcium mediated apoptotic damage of mitochondrial electron transport (14) . Cross-talk has been reported between caspases and calpains, a family of calcium-dependent proteases involved in apoptosis (38, 39) . Caspase inhibitors have been shown to inhibit calpain activity (38) , and both families of proteases share common targets, such as spectrin (39) . Our studies suggest a more direct effect, since we found that the inhibition of caspase-3 by calbindin was not calcium-dependent. Thus, calbindin may suppress apoptosis by inhibiting the activity of calcium-dependent proteases and by inhibiting caspase-3 via a calcium-independent mechanism.
Calbindin-D 28k Does Not Act as a Substrate of Caspase-3-The caspase-3 inhibitors viral p35 (40, 41) and viral serpin CrmA (42) are cleaved by the protease instead of the natural substrates. To determine whether calbindin acts similarly, purified calbindin-D 28k was incubated with caspase-3, and the resulting products were resolved by SDS-PAGE. As shown in Fig. 6A , calbindin-D 28k did not undergo any significant cleavage in the presence of caspase-3 (first and second lanes), whereas gelsolin, a previously demonstrated natural substrate of caspase-3 (43), was efficiently cleaved under similar conditions (third and fourth lanes). Calbindin-D 28k cleavage products were not observed, even after longer incubation in the presence of caspase-3 (30 min or 1 h, not shown). These results suggest that calbindin-D 28k does not require peptide bond hydrolysis as part of the mechanism of inhibition of caspase-3 activity. This is consistent with the fact that caspase-3 consensus cleavage sites are not found in the amino acid sequence of rat calbindin-D 28k (44, 45) . Interestingly, cleavage of gelsolin by caspase-3 was abolished by calbindin-D 28k (Fig. 6A, fifth  lane) , demonstrating that calbindin-D 28k blocks the degradation of both synthetic and natural substrates of caspase-3. As shown for DEVD-CHO degradation (Fig. 5) , other calcium proteins, including calmodulin, calbindin-D 9k , calretinin, and parvalbunin, did not inhibit the cleavage of gelsolin induced by caspase-3 (not shown).
Calbindin-D 28k Associates with Caspase-3-To gain insight into the mechanism by which calbindin inhibits caspase-3 activity, we evaluated the possibility that the two proteins interact by performing an in vitro binding assay. Bacterially expressed GST-calbindin-D 28k immobilized in glutathione beads was incubated with purified active caspase-3 and bound proteins were separated by SDS-PAGE. Western blot analysis using anti-caspase-3 antiserum indicated that indeed caspase-3 bound to GST-calbindin-D 28k , but not to control GST beads. These results indicate that inhibition of caspase-3 by calbindin-D 28k involves its association with the mature form of caspase-3. Whether calbindin-D 28k also binds to the inactive pro-caspase-3 inhibiting its processing will require further studies. Calbindin direct binding to the mature form of caspase-3 resembles the mechanism by which the inhibitor of apoptosis (IAP) family of proteins blocks several caspases (46) . The peptide aldehyde Ac-DEVD-CHO, a reversible inhibitor of caspase-3, undergoes nucleophilic addition of the cysteine at the catalytic site of caspase-3 to form a hemiacetal (33). Whether or not calbindin inhibits caspase-3 by interaction with its active site remains to be determined.
Recent evidence has demonstrated that the rate of bone formation is regulated not only by the rate of osteoblast formation but also by the rate of osteoblast apoptosis. Thus, increased osteoblast apoptosis is at least partially responsible for the reduced bone formation in glucocorticoid excess-induced osteopenia (5) . Conversely, inhibition of osteoblast apoptosis is a likely mechanism of the anabolic effect of intermittent administration of parathyroid hormone (6) . Consistent with the current studies, the inflammatory cytokine TNF␣, which inhibits bone formation, collagen synthesis, and alkaline phosphatase (47, 48) , has been reported to induce apoptosis of osteoblastic cells (4, 49, 50) . Growth factors such as insulin-like growth factor I, basic fibroblast growth factor, interleukin-6 type cytokines, and transforming growth factor ␤ inhibit osteoblastic cell apoptosis induced by TNF␣, serum deprivation, or activation of Fas (4, 49, 50) . Interestingly, insulin growth factor I and fibroblast growth factor induce calbindin-D 28k expression in neurons and promote neuronal survival (51) (52) (53) (54) . The induction of calbindin by these factors suggested a role for calbindin in the process of growth factor-mediated protection against neuronal cell death. Whether the survival effects of insulin growth factor and/or fibroblast growth factor are mediated through increases in calbindin expression in osteoblastic cells will require further studies.
In conclusion, the results of the studies reported herein demonstrate for the first time that calbindin-D 28k is unique among calcium-binding proteins in its ability to prevent osteoblast apoptosis by interaction and direct inhibition of caspase-3 activity. As opposed to all other reported actions of calbindin-D 28k , this effect appears to be independent of the calcium binding capabilities of the protein. Since osteoblastic cells seem to express significant amounts of this calcium binding protein, these observations could be of significance to in vivo bone biology.
